translation agency

NLM AIDSLINE
Autovaccination in ARC and AIDS patients: a clinical report and a statistical analysis of nearly 7 years therapy.
Bruster H; Illes A; Molling R; Lehnert E; Scheja J; Godehardt E;
December 30, 1992
Int Conf AIDS. 1992 Jul 19-24;8(3):60 (abstract no. PuB 7066). Unique

Overall 328 AIDS and ARC patients have been treated by the extended autovaccination pilot study since september 1986. A autologous heat inactivated HIV vaccine is weakly i.v. administered over a period of 6 weeks followed by a therapy pause of 6 weeks before starting the next cycle. Source material is obtained by weekly cytapheresis from individual patients. By this starting point the high and continuous spontaneous mutation rate of HIV is taken into account. It is striven for a stimulation of the immune system by the HIV peptides of the individual autovaccine preparation in the sense of an additional extracorporal antigen processing. This should help to trigger and conserve the repertoire of HIV specific immune response. Most of the patients are able to work and extensively free of opportunistic infections. In many cases a stabilisation of the CD-4 cell counts can be observed. CD-8 cell counts tend to increase or to stay constant. Enrichment of viral material in the autovaccine has been proven by in vitro experiments: p24 antigen is detectable in the lysate of mononuclear cells in high concentrations even if the donor of the specimen has been seronegative for p24 antigen. The actuarial survival rates (Kaplan-Meyer plot) are presented.

Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*THERAPY AIDS Vaccines/*THERAPEUTIC USE AIDS-Related Complex/IMMUNOLOGY/*THERAPY Human *Immunotherapy, Active ABSTRACT

www.aegis.org